Caladrius Biosciences Inc (NASDAQ:CLBS) stock is up in early morning trading, after Zacks Investment Research upgraded them from a “hold” to a “buy” rating.
Caladrius Biosciences creates immunotherapy treatments using their expertise in cell process optimization, development and manufacturing.
The stock is up 6.67% or $0.08 after the positive news, hitting $1.28 per share. About 15,600 shares traded hands. CLBS has declined 58.76% since April 24, 2015 and is downtrending. It has underperformed by 57.64% the S&P500.
Caladrius Biosciences, Inc., formerly NeoStem, Inc., is a clinical-stage biopharmaceutical company. The company has a market cap of $70.88 million. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It currently has negative earnings. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells .